Keywords
How to Cite
Abstract
To assess diagnostic capabilities of new receptor-specific radiopharmaceutical - prostate-specific membrane antigen labeled with gallium-68 (68Ga-PSMA) 66 patients with prostate cancer (PC) after radical prostatectomy underwent combined positron emission with computed tomography (PET/CT). In 61/66 cases PSA level was 0,2-1,0 ng/ml, in 5/66 it did not exceed 0,2 ng/ml. The processing of the results concluded in a visual analysis of the images. In 45/66 patients with PET foci of hyperfaxation of radiopharmaceutical were detected. At the same time structural changes in CT were determined only in 34/45 patients. PSMA-positive cases, not accompanied by radiographic findings, were attributed to false positive results. Indicators of PET/CT information without taking into account X-ray parameters of PSMA-positive changes had a greater diagnostic significance of the method in this category of patients. PET/CT with 68Ga-PSMA is a promising method for diagnosing biochemical recurrence of PC at low PSA values.References
N. Mottet, J. Bellmunt, E. Briers et. al. EAU guidelines on prostate cancer: part 6: disease management//Eur. Urol. -2016. -Vol. 74.
Pound C.R. et al. Natural history of progression after PsA elevation following radical prostatectomy//JAMA. -1999. -Vol. 281. -P. 1591.
Sella T., Schwartz L.H., Swindle P.W., Onyebuchi C.N. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging//Radiology. -2004. -Vol. 231(2). -P 279-385.
Krause B.J., Souvatzoglou M., Tuncel M. et al. The detection rate of Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer//Eur. J. Nucl. Med. Mol. Imaging. -2008. -Vol. 35. -P. 18-23.
T. Mauer, M. Eiber. Current use of PSMA-PET in prostate cancer management. i:. Nature reviews//Urology. -2016. DOI: 10.1038/nrurol.2016.26
Martina Benesova, Martin Schfer, Ulrike Bauder-Wst, Ali Afshar-Oromieh et. al. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer//J. Nucl. Med. -2015. -Vol. 56. -P. 914-920.
Schuhmacher J., Maier-Borst W. (1981) A new Ge-68/Ga68 radioisotope generator system for production of Ga-68 in dilute HCl//Int. J. Appl. Radiat. Isot. -1981. -Vol. 32. -P. 31 36.
Ali Afshar-Oromieh et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients//Eur. J. Nucl. Med. Mol. Imaging. -2017.
Кодина Г.Е., Козлова М.Д., Краснов H.H., Малинин А.Б. и др. Радионуклидный генератор 68Ge/68Ga для получения физиологически приемлемого раствора. -Патент РФ №2126271, 1998.
Tlostanova M.S., Khodzhibekova М.М., Panfilenko А.А., Balabanova А.А., et. al. Capabilities of combined positron emission and computed tomography in neuroendocrine tumor diagnostics: first experience of Russian synthesis module 68Ga-DOTA-TATE//Sovremennye tehnologii v medicine. -2016. -Vol. 8(4). -P. 51-58.
Brogsitter C., Zphel K., Kotzerke J. 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients//Eur. J. Nucl. Med. Mol. Imaging. -2013. -Vol. 40. -P 18-27.
Afshar-Oromieh A., Avtzi E., Giesel F.L. et al. The diagnostic value of PET/CT imaging with the (68)Galabelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer//Eur. J. Nucl. Med. Mol. Imaging. -2015. -Vol. 42. -P 197-207.
Matthias Eiber, Tobias Maurer. Evaluation of hybrid 68Ga-PSMA-ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy//Journal of Nuclear Medicine. -2015.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2018